Programmed death ligand 1 (PDL-1) expression in triple negative breast cancer cells: New proposal for a "tumor score" definition

Maurizio Di Bonito; Giosuè Scognamiglio; Francesca Collina; Giuseppina Liguori; Monica Cantile; Gerardo Botti

Programmed death ligand 1 (PDL-1) expression in triple negative breast cancer cells: New proposal for a "tumor score" definition

Maurizio Di Bonito, Giosuè Scognamiglio, Francesca Collina, Giuseppina Liguori, Monica Cantile, Gerardo Botti

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Abstract

Recently, several studies showed that PDL-1 pathway may have a key role in the interaction of tumor cells with host immune response, and PDL-1 expression of tumor cells may serve as a mechanism of adaptive immune resistance. The data available in the literature about PDL-1 immunohistochemical expression in tumor tissues are not uniform, for the use of different antibodies clones and the absence of a standardized operative protocol. In this study we analyzed PDL-1 expression in a series of triple negative breast cancers and defined a standardized protocol suggesting a "tumor score" for its evaluation. Its application on large tumor case series will allow to investigate the real prognostic value of PD-L1.

Original language	English
Pages (from-to)	11693-11696
Number of pages	4
Journal	International Journal of Clinical and Experimental Pathology
Volume	9
Issue number	11
Publication status	Published - 2016

Keywords

PD-L1
TNBC
Tumor score

ASJC Scopus subject areas

Pathology and Forensic Medicine
Histology

Fingerprint Dive into the research topics of 'Programmed death ligand 1 (PDL-1) expression in triple negative breast cancer cells: New proposal for a "tumor score" definition'. Together they form a unique fingerprint.

Cite this

Programmed death ligand 1 (PDL-1) expression in triple negative breast cancer cells : New proposal for a "tumor score" definition. / Di Bonito, Maurizio ; Scognamiglio, Giosuè ; Collina, Francesca ; Liguori, Giuseppina ; Cantile, Monica ; Botti, Gerardo.

In: International Journal of Clinical and Experimental Pathology, Vol. 9, No. 11, 2016, p. 11693-11696.

Research output: Contribution to journal › Article › peer-review

@article{b3df623833c54e6594e2648c1f828b96,

title = "Programmed death ligand 1 (PDL-1) expression in triple negative breast cancer cells: New proposal for a {"}tumor score{"} definition",

abstract = "Recently, several studies showed that PDL-1 pathway may have a key role in the interaction of tumor cells with host immune response, and PDL-1 expression of tumor cells may serve as a mechanism of adaptive immune resistance. The data available in the literature about PDL-1 immunohistochemical expression in tumor tissues are not uniform, for the use of different antibodies clones and the absence of a standardized operative protocol. In this study we analyzed PDL-1 expression in a series of triple negative breast cancers and defined a standardized protocol suggesting a {"}tumor score{"} for its evaluation. Its application on large tumor case series will allow to investigate the real prognostic value of PD-L1.",

keywords = "PD-L1, TNBC, Tumor score",

author = "{Di Bonito}, Maurizio and Giosu{\`e} Scognamiglio and Francesca Collina and Giuseppina Liguori and Monica Cantile and Gerardo Botti",

year = "2016",

language = "English",

volume = "9",

pages = "11693--11696",

journal = "International Journal of Clinical and Experimental Pathology",

issn = "1936-2625",

publisher = "E-CENTURY PUBLISHING CORP",

number = "11",

}

TY - JOUR

T1 - Programmed death ligand 1 (PDL-1) expression in triple negative breast cancer cells

T2 - New proposal for a "tumor score" definition

AU - Di Bonito, Maurizio

AU - Scognamiglio, Giosuè

AU - Collina, Francesca

AU - Liguori, Giuseppina

AU - Cantile, Monica

AU - Botti, Gerardo

PY - 2016

Y1 - 2016

N2 - Recently, several studies showed that PDL-1 pathway may have a key role in the interaction of tumor cells with host immune response, and PDL-1 expression of tumor cells may serve as a mechanism of adaptive immune resistance. The data available in the literature about PDL-1 immunohistochemical expression in tumor tissues are not uniform, for the use of different antibodies clones and the absence of a standardized operative protocol. In this study we analyzed PDL-1 expression in a series of triple negative breast cancers and defined a standardized protocol suggesting a "tumor score" for its evaluation. Its application on large tumor case series will allow to investigate the real prognostic value of PD-L1.

AB - Recently, several studies showed that PDL-1 pathway may have a key role in the interaction of tumor cells with host immune response, and PDL-1 expression of tumor cells may serve as a mechanism of adaptive immune resistance. The data available in the literature about PDL-1 immunohistochemical expression in tumor tissues are not uniform, for the use of different antibodies clones and the absence of a standardized operative protocol. In this study we analyzed PDL-1 expression in a series of triple negative breast cancers and defined a standardized protocol suggesting a "tumor score" for its evaluation. Its application on large tumor case series will allow to investigate the real prognostic value of PD-L1.

KW - PD-L1

KW - TNBC

KW - Tumor score

UR - http://www.scopus.com/inward/record.url?scp=85006141718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006141718&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85006141718

VL - 9

SP - 11693

EP - 11696

JO - International Journal of Clinical and Experimental Pathology

JF - International Journal of Clinical and Experimental Pathology

SN - 1936-2625

IS - 11

ER -